9 results
-
List item
Human medicine European public assessment report (EPAR): Cymbalta
duloxetine, Anxiety Disorders; Diabetic Neuropathies; Depressive Disorder, Major
Date of authorisation: 17/12/2004, Revision: 32, Authorised, Last updated: 27/06/2023 -
List item
Human medicine European public assessment report (EPAR): Nodetrip (previously Xeristar)
duloxetine, Anxiety Disorders; Depressive Disorder, Major; Diabetic Neuropathies
Date of authorisation: 17/12/2004, Revision: 32, Withdrawn, Last updated: 22/06/2021 -
List item
Orphan designation: Autologous urothelial and smooth muscle cells for: Treatment of spina bifida
Date of designation: 18/03/2008, Withdrawn, Last updated: 24/05/2012 -
List item
Orphan designation: Autologous urothelial and smooth muscle cells for: Treatment of spinal cord injury
Date of designation: 08/11/2008, Withdrawn, Last updated: 24/05/2012 -
List item
Orphan designation: Guanabenz for: Treatment of traumatic spinal cord injury
Date of designation: 29/04/2009, Positive, Last updated: 12/05/2009Associazione Studio Atrofie Muscolari Spinali Infantili - ONLUS … -
List item
Public data from Article 57 database
Last updated: 09/10/2023 -
List item
Article 141(1) opinions on any scientific matter: veterinary medicines
Last updated: 22/06/2023 -
List item
Press release: Diclofenac use in animals poses a risk to European vultures
CVMP, Last updated: 12/12/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 June 2018
European Medicines Agency, London, UK, from 11/06/2018 to 14/06/2018, Last updated: 10/08/2018